false
0000827871
0000827871
2023-11-27
2023-11-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d)
of the Securities
Exchange Act of 1934
Date of Report (Date of
earliest event reported): November 27, 2023
Eagle Pharmaceuticals, Inc.
(Exact Name of Registrant
as Specified in its Charter)
Delaware |
001-36306 |
20-8179278 |
(State
or Other Jurisdiction
of Incorporation) |
(Commission
File Number) |
(IRS Employer Identification No.) |
50 Tice Boulevard, Suite 315
Woodcliff Lake, NJ |
|
07677 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (201) 326-5300
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
symbol(s) |
|
Name
of each exchange on which registered |
Common Stock, par value $0.001 per share |
|
EGRX |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Transfer of Listing.
On November 27,
2023, Eagle Pharmaceuticals, Inc. (the “Company”) received a delinquency
notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying the Company that due to the delay in filing the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30,
2023 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”),
which requires listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the “SEC”).
The Notice
provides that the Company has 60 calendar days from the date of the Notice, or until January 26, 2024, to submit to Nasdaq a
plan to regain compliance with the Rule. If Nasdaq accepts the plan, Nasdaq may grant the Company an exception of up to 180 calendar
days from the due date of the Form 10-Q, or until May 7, 2024, to regain compliance. The Company may be able to regain
compliance with the Rule by filing the Form 10-Q with the SEC (and any other reports required to be filed) before the end
of any such exception period. If the Company fails to regain compliance prior to the expiration of any such exception period or if
Nasdaq does not accept the plan of compliance, Nasdaq will issue a determination indicating that the Company is subject to
delisting. If that occurs, the Company may request a hearing before a Hearing Panel to review the determination. However, there can
be no assurance that Nasdaq will accept such plan or grant an exception period, that any hearing would be successful, or that
the Company will be able to regain compliance within the deadline or any exception period that may be granted or maintain
compliance with the other continued listing requirements set forth in the Nasdaq Listing Rules.
Item 7.01 Regulation FD Disclosure.
On November 29,
2023, the Company issued a press release announcing the Company’s receipt of the Notice. A copy of the press release is furnished
as Exhibit 99.1 to this Current Report on Form 8-K.
The
information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18
of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into
any of the Company’s filings under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether
made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set
forth by specific reference in such filing..
Forward-Looking Statements
This current
report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, and other securities law. Forward-looking statements are statements that are not historical facts.
Words and phrases such as “anticipated,” “forward,” “will,” “would,”
“could,” “may,” “remain,” “potential,” “prepare,”
“expected,” “believe,” “plan,” “and similar expressions are intended to identify
forward-looking statements. These statements include, but are not limited to, statements with respect to: statements relating to the
Company’s SEC filings and the timing thereof, the potential submission of a plan to Nasdaq and the potential for Nasdaq to
accept such plan or grant the Company an exception period or the success of any hearing process, and the Company’s ability to
regain compliance with the Nasdaq continued listing standards. All of such statements are subject to certain risks and
uncertainties, many of which are difficult to predict and generally beyond the Company’s control, that could cause actual
results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.
Such risks and uncertainties include, but are not limited to: the completion of the review and
preparation of the Company’s financial statements and the
timing thereof, the discovery of additional information, further delays in the Company’s financial reporting, including as a
result of unanticipated factors, the possibility that the Company is unable to regain compliance with, or thereafter continue to
comply with, the Nasdaq Listing Rules, or experience violations of additional Nasdaq Listing Rules, the possibility that the Nasdaq
may delist the Company’s securities and the risks and uncertainties set forth in the sections entitled “Risk
Factors” in the Company's Annual Report on Form 10-K for the
year ended December 31, 2022, and in its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023 and
June 30, 2023, as well as subsequent filings with the SEC. The Company does not give any assurance that it will achieve its
expectations. Readers are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements
contained in this current report on Form 8-K speak only as of the date on which they were made. Except to the extent required
by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: November 29, 2023 |
|
EAGLE PHARMACEUTICALS, INC. |
|
|
|
By: |
/s/ Brian Cahill |
|
|
Brian Cahill |
|
|
Chief Financial Officer |
Exhibit 99.1
Eagle
Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on
Form 10-Q
WOODCLIFF
LAKE, N.J. — November 29, 2023 — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today
announced that it received a notice (the “Notice”) on November 27, 2023 from the Listing Qualifications Department
of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not currently in compliance with
Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which
requires timely filing of all required periodic financial reports with the Securities and Exchange Commission (the
“SEC”), as a result of the Company’s failure to file its Quarterly Report on Form 10-Q for the quarter ended
September 30, 2023 (the “Form 10-Q”) within the prescribed timeframe.
The Notice
provides that the Company has 60 calendar days from the date of the Notice, or until January 26, 2024, to submit to Nasdaq a
plan to regain compliance with the Rule. If Nasdaq accepts the plan, Nasdaq may grant the Company an exception of up to 180 calendar
days from the due date of the Form 10-Q, or until May 7, 2024, to regain compliance. The Company may be able to regain
compliance with the Rule by filing the Form 10-Q with the SEC (and any other reports required to be filed) before the end
of any such exception period. If the Company fails to regain compliance prior to the expiration of any such exception period or if
Nasdaq does not accept the plan of compliance, Nasdaq will issue a determination indicating that the Company is subject to
delisting. If that occurs, the Company may request a hearing before a Hearing Panel to review the determination. However, there can
be no assurance that Nasdaq will accept such plan or grant an exception period, that any hearing would be successful, or that the
Company will be able to regain compliance within the deadline or any exception period that may be granted or maintain compliance
with the other continued listing requirements set forth in the Nasdaq Listing Rules.
About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical
company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative
medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®,
RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary
Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to
address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential
to become part of the personalized medicine paradigm in cancer care. Additional information is available on Eagle’s website at
www.eagleus.com.
Forward-Looking
Statements Disclaimer
This press
release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of
1995, as amended, and other securities law. Forward-looking statements are statements that are not historical facts. Words and
phrases such as “anticipated,” “forward,” “will,” “would,” “could,”
“may,” “remain,” “potential,” “prepare,” “expected,”
“believe,” “plan,” “and similar expressions are intended to identify forward-looking statements. These
statements include, but are not limited to, statements with respect to: statements relating to the Company’s SEC filings and
the timing thereof, the potential submission of a plan to Nasdaq and the potential for Nasdaq to accept such plan or grant the
Company an exception period or the success of any hearing process, and the Company’s ability to regain compliance with the
Nasdaq continued listing standards. All of such statements are subject to certain risks and uncertainties, many of which are
difficult to predict and generally beyond the Company’s control, that could cause actual results to differ materially from
those expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties
include, but are not limited to: the completion of the review and preparation of the Company’s financial statements and the timing thereof, the discovery of additional information,
further delays in the Company’s financial reporting, including as a result of unanticipated factors, the possibility that the
Company is unable to regain compliance with, or thereafter continue to comply with, the Nasdaq Listing Rules, or experience
violations of additional Nasdaq Listing Rules, the possibility that the Nasdaq may delist the Company’s securities and the
risks and uncertainties set forth in the sections entitled “Risk Factors” in the Company's Annual Report on
Form 10-K for the year ended December 31, 2022, and in its Quarterly Reports on Form 10-Q for the quarters ended
March 31, 2023 and June 30, 2023, as well as subsequent filings with the SEC. The Company does not give any assurance that
it will achieve its expectations. Readers are cautioned not to place undue reliance on forward-looking statements. All
forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent
required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
Investor
Relations Contacts:
Lisa Wilson
In-Site Communications, Inc.
917-543-9932
lwilson@insitecony.com
Timothy
McCarthy, CFA
917-679-9282
tim@lifesciadvisors.com
# # #
v3.23.3
Cover
|
Nov. 27, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 27, 2023
|
Entity File Number |
001-36306
|
Entity Registrant Name |
Eagle Pharmaceuticals, Inc.
|
Entity Central Index Key |
0000827871
|
Entity Tax Identification Number |
20-8179278
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
50 Tice Boulevard
|
Entity Address, Address Line Two |
Suite 315
|
Entity Address, City or Town |
Woodcliff Lake
|
Entity Address, State or Province |
NJ
|
Entity Address, Postal Zip Code |
07677
|
City Area Code |
201
|
Local Phone Number |
326-5300
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.001 per share
|
Trading Symbol |
EGRX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Apr 2023 to Apr 2024